Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease

被引：0
|
作者：
Umesh Gangishetti
J. Christina Howell
Richard J. Perrin
Natalia Louneva
Kelly D. Watts
Alexander Kollhoff
Murray Grossman
David A. Wolk
Leslie M. Shaw
John C. Morris
John Q. Trojanowski
Anne M. Fagan
Steven E. Arnold
William T. Hu
机构：
[1] Emory University,Department of Neurology
[2] Emory University,Department of Alzheimer’s Disease Research Center
[3] Washington University,Knight Alzheimer’s Disease Research Center
[4] Washington University,Department of Pathology
[5] Washington University,Department of Neurology
[6] University of Pennsylvania,Penn Memory Center
[7] University of Pennsylvania,Center for Neurodegenerative Disease Research
[8] University of Pennsylvania,Penn FTD Center
[9] University of Pennsylvania,Department of Neurology
[10] University of Pennsylvania,Department of Pathology and Laboratory Medicine
[11] Present Address: Massachusetts General Hospital,undefined
来源：
Alzheimer's Research & Therapy | / 10卷
关键词：
Biomarkers; Fatty acid binding protein; Interleukin-10; Mild cognitive impairment; Neurofilament light chain;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [11] Cerebrospinal fluid levels of Aβ42 and tau:: potential markers of Alzheimer's disease
    Galasko, D
    JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT, 1998, (53): : 209 - 221
  • [12] Amyloid-beta and tau proteins as biochemical markers of Alzheimer's disease
    Sobów, T
    Flirski, M
    Liberski, PP
    ACTA NEUROBIOLOGIAE EXPERIMENTALIS, 2004, 64 (01) : 53 - 70
  • [13] Amyloid beta 1-42 and tau in the cerebrospinal fluid of renal failure patients for the diagnosis of Alzheimer's disease
    Shea, Yat Fung
    Chu, Leung-wing
    Mok, Ming-yee Maggie
    Lam, Man-Fai
    JOURNAL OF NEPHROLOGY, 2014, 27 (02) : 217 - 220
  • [14] Rapid multiplexed detection of beta-amyloid and total-tau as biomarkers for Alzheimer's disease in cerebrospinal fluid
    Song, Chao
    Deng, Pan
    Que, Long
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2018, 14 (06) : 1845 - 1852
  • [15] Tau oligomers in cerebrospinal fluid in Alzheimer's disease
    Sengupta, Urmi
    Portelius, Erik
    Hansson, Oskar
    Farmer, Kathleen
    Castillo-Carranza, Diana
    Woltjer, Randall
    Zetterberg, Henrik
    Galasko, Douglas
    Blennow, Kaj
    Kayed, Rakez
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2017, 4 (04): : 226 - 235
  • [16] Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Alzheimer's and Parkinson's disease
    Stefanova, E.
    Markovic, I.
    Mandic-Stojmenovic, G.
    Stojkovic, T.
    Lukic, M. Jecmenica
    Kostic, V.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 351 - 351
  • [17] Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease
    Jing Zhang
    Hayley A. Mattison
    Changqin Liu
    Carmen Ginghina
    Peggy Auinger
    Michael P. McDermott
    Tessandra Stewart
    Un Jung Kang
    Kevin C. Cain
    Min Shi
    Acta Neuropathologica, 2013, 126 : 671 - 682
  • [18] Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease
    Zhang, Jing
    Mattison, Hayley A.
    Liu, Changqin
    Ginghina, Carmen
    Auinger, Peggy
    McDermott, Michael P.
    Stewart, Tessandra
    Kang, Un Jung
    Cain, Kevin C.
    Shi, Min
    ACTA NEUROPATHOLOGICA, 2013, 126 (05) : 671 - 682
  • [19] Effect of genetic risk factors and disease progression on the cerebrospinal fluid tau levels in Alzheimer's disease
    Arai, H
    Terajima, M
    Miura, M
    Higuchi, S
    Muramatsu, T
    Matsushita, S
    Machida, N
    Nakagawa, T
    Lee, VMY
    Trojanowski, JQ
    Sasaki, H
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1997, 45 (10) : 1228 - 1231
  • [20] Alzheimer’s disease risk variants show association with cerebrospinal fluid amyloid beta
    John S. K. Kauwe
    Jun Wang
    Kevin Mayo
    John C. Morris
    Anne M. Fagan
    David M. Holtzman
    Alison M. Goate
    neurogenetics, 2009, 10 : 13 - 17
12345